PL2241564T3 - Pochodna 3,8-diaminotetrahydrochinoliny - Google Patents

Pochodna 3,8-diaminotetrahydrochinoliny

Info

Publication number
PL2241564T3
PL2241564T3 PL09707360T PL09707360T PL2241564T3 PL 2241564 T3 PL2241564 T3 PL 2241564T3 PL 09707360 T PL09707360 T PL 09707360T PL 09707360 T PL09707360 T PL 09707360T PL 2241564 T3 PL2241564 T3 PL 2241564T3
Authority
PL
Poland
Prior art keywords
diaminotetrahydroquinoline
derivative
diaminotetrahydroquinoline derivative
Prior art date
Application number
PL09707360T
Other languages
English (en)
Inventor
Takeshi Watanabe
Masaru Terauchi
Masaaki Nagasawa
Kouichirou Tanaka
Masataka Washiduka
Original Assignee
Zeria Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeria Pharm Co Ltd filed Critical Zeria Pharm Co Ltd
Publication of PL2241564T3 publication Critical patent/PL2241564T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
PL09707360T 2008-02-08 2009-02-06 Pochodna 3,8-diaminotetrahydrochinoliny PL2241564T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2008029781 2008-02-08
JP2008277044 2008-10-28
EP09707360.5A EP2241564B1 (en) 2008-02-08 2009-02-06 3,8-diaminotetrahydroquinoline derivative
PCT/JP2009/000487 WO2009098901A1 (ja) 2008-02-08 2009-02-06 3,8-ジアミノテトラヒドロキノリン誘導体

Publications (1)

Publication Number Publication Date
PL2241564T3 true PL2241564T3 (pl) 2014-09-30

Family

ID=40951980

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09707360T PL2241564T3 (pl) 2008-02-08 2009-02-06 Pochodna 3,8-diaminotetrahydrochinoliny

Country Status (20)

Country Link
US (2) US8299255B2 (pl)
EP (1) EP2241564B1 (pl)
JP (1) JP5493870B2 (pl)
KR (1) KR101553725B1 (pl)
CN (1) CN101939313B (pl)
AU (1) AU2009212645B2 (pl)
BR (1) BRPI0907749A2 (pl)
CA (1) CA2714480C (pl)
CY (1) CY1115138T1 (pl)
DK (1) DK2241564T3 (pl)
ES (1) ES2464342T3 (pl)
HR (1) HRP20140449T1 (pl)
MX (1) MX2010008740A (pl)
PL (1) PL2241564T3 (pl)
PT (1) PT2241564E (pl)
RU (1) RU2482117C2 (pl)
SI (1) SI2241564T1 (pl)
TW (1) TWI422585B (pl)
WO (1) WO2009098901A1 (pl)
ZA (1) ZA201005346B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8809369B2 (en) * 2011-01-26 2014-08-19 Hoffmann-La Roche Inc. Tetrahydroquinoline derivatives
WO2014156339A1 (ja) 2013-03-25 2014-10-02 ゼリア新薬工業株式会社 食後期の胃運動亢進剤
CN104193722A (zh) * 2014-08-27 2014-12-10 湖南华腾制药有限公司 一种n-叔丁氧羰基-3-甲胺噻吩的制备方法
KR20230031207A (ko) * 2020-06-30 2023-03-07 도레이 카부시키가이샤 대사이상을 수반하는 질환 또는 증후군에 있어서의 근력 저하 증상의 개선제 또는 예방제

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206235A (en) * 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
JP3817746B2 (ja) 1994-06-20 2006-09-06 株式会社竹屋 パチンコ島台
AU758160B2 (en) * 1997-08-22 2003-03-20 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives
US6211174B1 (en) * 1997-10-31 2001-04-03 Merck & Co., Inc. Naphtho-fused lactams promote release of growth hormone
UA73530C2 (uk) 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
RU2277092C2 (ru) * 2000-09-15 2006-05-27 Анормед, Инк. Гетероциклические соединения, их применение и фармацевтическая композиция для лечения состояний, опосредованных схсr4 и ccr5
WO2005007628A1 (en) * 2003-07-11 2005-01-27 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives as cannabinoid receptor modulators
WO2008116107A2 (en) 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators

Also Published As

Publication number Publication date
HRP20140449T1 (hr) 2014-06-20
BRPI0907749A2 (pt) 2015-07-21
ES2464342T3 (es) 2014-06-02
US8299255B2 (en) 2012-10-30
MX2010008740A (es) 2010-08-30
RU2482117C2 (ru) 2013-05-20
JP5493870B2 (ja) 2014-05-14
AU2009212645B2 (en) 2012-07-19
CN101939313A (zh) 2011-01-05
CA2714480A1 (en) 2009-08-13
US20100317693A1 (en) 2010-12-16
KR101553725B1 (ko) 2015-09-16
CN101939313B (zh) 2013-05-22
EP2241564A1 (en) 2010-10-20
TWI422585B (zh) 2014-01-11
AU2009212645A1 (en) 2009-08-13
WO2009098901A1 (ja) 2009-08-13
TW200940530A (en) 2009-10-01
SI2241564T1 (sl) 2014-06-30
JPWO2009098901A1 (ja) 2011-05-26
ZA201005346B (en) 2011-11-30
DK2241564T3 (da) 2014-05-19
KR20100116175A (ko) 2010-10-29
PT2241564E (pt) 2014-06-12
US8501772B2 (en) 2013-08-06
RU2010137336A (ru) 2012-03-20
EP2241564A4 (en) 2011-07-20
CA2714480C (en) 2017-03-28
CY1115138T1 (el) 2016-12-14
EP2241564B1 (en) 2014-04-30
US20130012537A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
HUS2400041I1 (hu) 4-Pirimidin-szulfamid-származék
IL206765A0 (en) 4,5-dihydro-oxazol-2-yl-amine derivatives
EP2361902A4 (en) 4,6-DIAMINONICOTINSÄUREAMIDVERBINDUNG
IL201973A0 (en) 3,3-spiroindolinone derivatives
IL213787A0 (en) Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds
ZA200908298B (en) Bicycloaniline derivative
ZA201006993B (en) Substituted pyrimidin-5-carboxamides 281
ZA201001797B (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
ZA201102315B (en) 7-piperidinoalkyl-3,4-dihyfroquinolone derivative
EP2241567A4 (en) Bicycloamine DERIVATIVE
SI2356123T1 (sl) Piro-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo(e)azuleni
SI2513119T1 (sl) 3,4,4a,10b-tetrahidro-1H-tiopirano-(4,3-c)izokinolinski derivati
EP2163554A4 (en) PYRIMIDODIAZEPINONE DERIVATIVE
EP2202231A4 (en) 2,3-DIHYDROIMINOISOINDOLE DERIVATIVE
ZA201005346B (en) 3,8-diaminotetrahydroquinoline derivative
IL201444A0 (en) New 4, 8 - diphenyl - polyazanaphthalene derivatives
IL213762A0 (en) 1,1,1-trifluoro-2-hydroxypropyl compounds
GB0905087D0 (en) Cypardon 2
IL219623A0 (en) [1,5]-diazocin derivatives
GB0813815D0 (en) Corcost Pre 1001,10
GB0808811D0 (en) Algabe 2.1
GB0808042D0 (en) Advance 002
PL384214A1 (pl) Drzwi, zwłaszcza do więzień i aresztów
GB0810603D0 (en) Corcost prepost 001
GB0808846D0 (en) 10000002